Wellington Management Group LLP Decreases Stake in Repligen Co. (NASDAQ:RGEN)

Wellington Management Group LLP lessened its stake in Repligen Co. (NASDAQ:RGEN) by 21.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,101,497 shares of the biotechnology company’s stock after selling 295,113 shares during the quarter. Wellington Management Group LLP owned 1.98% of Repligen worth $198,049,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. DekaBank Deutsche Girozentrale lifted its stake in Repligen by 1.5% during the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock worth $1,663,000 after purchasing an additional 159 shares during the last quarter. QRG Capital Management Inc. purchased a new stake in Repligen during the third quarter worth approximately $444,000. Envestnet Portfolio Solutions Inc. purchased a new stake in Repligen during the third quarter worth approximately $585,000. Envestnet Asset Management Inc. lifted its stake in Repligen by 39.7% during the third quarter. Envestnet Asset Management Inc. now owns 106,379 shares of the biotechnology company’s stock worth $16,915,000 after purchasing an additional 30,239 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Repligen by 2.4% during the third quarter. Northern Trust Corp now owns 471,919 shares of the biotechnology company’s stock worth $75,040,000 after purchasing an additional 11,204 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 1.1 %

NASDAQ:RGEN opened at $123.00 on Wednesday. The firm has a market cap of $6.87 billion, a P/E ratio of 492.02, a PEG ratio of 4.19 and a beta of 1.04. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock’s 50 day simple moving average is $158.40 and its 200-day simple moving average is $176.02. Repligen Co. has a 12-month low of $110.45 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.64 EPS. Equities analysts anticipate that Repligen Co. will post 1.46 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on RGEN. Stifel Nicolaus boosted their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Guggenheim initiated coverage on Repligen in a research report on Tuesday. They set a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. cut their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $197.75.

Insider Activity

In related news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Martin D. Madaus acquired 1,615 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were acquired at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the acquisition, the director now directly owns 4,613 shares of the company’s stock, valued at $576,348.22. The disclosure for this purchase can be found here. Corporate insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.